Title :

Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy

Author(s) :

Leclair-Visonneau, Laurene [Auteur]
Rouaud, Tiphaine [Auteur]
Debilly, Berangere [Auteur]
Durif, Franck [Auteur]
Houeto, Jean-Luc [Auteur]
Kreisler, Alexandre [Auteur]

Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172

DEFEBVRE, Luc [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Lamy, Estelle [Auteur]
Volteau, Christelle [Auteur]
Nguyen, Jean-Michel [Auteur]
Dily, Severine Le [Auteur]
Damier, Philippe [Auteur]
Boutoleau-Bretonniere, Claire [Auteur]
Lejeune, Pascal [Auteur]
Derkinderen, Pascal [Auteur]

Journal title :

Clinical neurology and neurosurgery

Abbreviated title :

Clin. Neurol. Neurosurg.

Volume number :

146

Pages :

35-39

Publication date :

2016-07-01

ISSN :

0303-8467

English keyword(s) :

Neuroprotection
Sodium valproate
Controlled-trial
Progressive supranuclear palsy

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

OBJECTIVE: Results from preclinical studies suggest that inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for tauopathies. The aim of the present study was therefore to determine the effects of sodium ...
Show more >OBJECTIVE: Results from preclinical studies suggest that inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for tauopathies. The aim of the present study was therefore to determine the effects of sodium valproate (VPA), a GSK-3 inhibitor, on disease progression in progressive supranuclear palsy (PSP). METHODS: We performed a double-blind, randomized, placebo-controlled trial, in 28 PSP patients who received VPA (1500mg/day) or matching placebo for 24 months. The primary endpoint was the change from baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at 12 and 24 months. Secondary endpoints evaluated the effects of VPA on cognitive and behavioral status (MMSE, Mattis Dementia Rating Scale, Wisconsin Card Sorting, Gröber and Buschke and Oral Denomination 80 tests), tolerability of treatment, and patient compliance. RESULTS: There were no baseline differences between active treatment and placebo groups in age and clinical rating scores. PSPRS score at 12 months was significantly higher in the VPA than in the placebo group (60.8±20 versus 46.9±18.6 respectively, p=0.01), but was similar between the two groups at 24 months. No significant differences were observed between VPA and placebo groups for the secondary endpoints. CONCLUSIONS: Our results suggest that VPA is not effective as a disease-modifying agent in PSP.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Submission date :

2019-11-27T14:28:35Z